2024-11-21 - Analysis Report
## Vertex Pharmaceuticals Inc. (VRTX) Stock Report

**1. Performance Comparison and Divergence:**

Vertex Pharmaceuticals (VRTX) has significantly outperformed the S&P 500 (VOO) over the analyzed period.  The cumulative return for VRTX is 166.8%, while the S&P 500's cumulative return is 125.68%. This results in a difference of 41.12%, placing it at the 67.68th percentile of the historical range of divergence (max: 94.07%, min: -69.76%).  Vertex Pharmaceuticals Inc. is a biotechnology company focused on the discovery, development and commercialization of therapies for cystic fibrosis and other genetic diseases.

**Alpha and Beta Analysis:**

The provided data shows VRTX exhibiting high alpha values (above 1) in several periods, suggesting consistent outperformance relative to the market benchmark.  Beta values generally decrease over time indicating reduced market sensitivity.  However, high volatility (MDD) is also evident in some periods.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 21.8% | 32.2% | -16.6% | 1.6 | 38.6 |
| 2016-2018  | 34.8% | 31.5% | 2.5% | 1.5 | 42.7 |
| 2017-2019  | 192.4% | 19.1% | 140.7% | 1.2 | 56.4 |
| 2018-2020  | 54.6% | 30.4% | 7.2% | 0.9 | 60.9 |
| 2019-2021  | 33.8% | 34.7% | -66.2% | 0.8 | 56.5 |
| 2020-2022  | 31.6% | 34.7% | 8.0% | 0.7 | 74.4 |
| 2021-2023  | 77.3% | 21.3% | 42.4% | 0.6 | 104.8 |
| 2022-2024  | 102.8% | 18.8% | 73.8% | 0.6 | 115.4 |


**2. Recent Price Movement:**

* **Closing Price:** $451.23 (Last Market: $451.14)
* **5-Day Moving Average:** $463.18
* **20-Day Moving Average:** $480.31
* **60-Day Moving Average:** $475.93

The stock is currently trading below its 5, 20, and 60-day moving averages, suggesting a short-term bearish trend.


**3. Technical Indicators:**

* **RSI (41.57):**  Indicates the stock is currently in oversold territory, suggesting potential for a bounce.
* **PPO (-1.08):**  Negative value shows bearish momentum.
* **Delta_Previous_Relative_Divergence (-10.0):** Shows a recent decline in relative strength.
* **Expected Return (17.79%):**  Suggests significant outperformance potential compared to the S&P 500 over the long term (2+ years).  This is a key positive factor.  The closing price of $451.14 is not significantly different from the last market price, so no sudden price movements are indicated.


**4. Recent Financial Performance and Outlook:**

The provided EPS data shows volatility.  While recent quarters have shown positive EPS, the August 2024 result was significantly negative.  More context and analyst forecasts are needed for a complete assessment.  The revenue generally shows a positive and increasing trend.  A review of the most recent earnings report is crucial for context.  We need the associated forecast to evaluate the November 5th, 2024 result.


| Date       | EPS     | Revenue    |
|------------|---------|------------|
| 2024-11-05 | 4.05    | $2.77 B    |
| 2024-08-02 | -13.92  | $2.65 B    |
| 2024-05-07 | 4.26    | $2.69 B    |
| 2023-11-07 | 4.01    | $2.48 B    |
| 2024-11-05 | 4.01    | $2.48 B    |  *(Note: Duplicate entry?)*


**6. Financial Information Analysis:**

* **Revenue and Profitability:**  Revenue has shown consistent growth.  Profit margins are high and relatively stable, indicating strong operational efficiency.

* **Capital and Profitability:** ROE shows significant variability, highlighting the inherent risk and volatility associated with a biotech company.  The large equity suggests a strong financial foundation.


**7. News and Recent Issues:**

*(This section requires real-time data gathering.  I need access to current news sources like Seeking Alpha, Yahoo Finance, and others to provide an accurate summary of recent news, analyst opinions, and market outlooks.  Please provide links to relevant news articles.)*


**8. Overall Analysis:**

VRTX shows a strong track record of outperformance compared to the S&P 500, evidenced by its high cumulative returns and positive alpha. However, the stock exhibits high volatility and its recent financial performance contains some uncertainties.  The current technical indicators suggest a potential short-term bounce, but long-term prospects depend largely on future drug development success and regulatory approvals.  A thorough analysis of the latest earnings report and news concerning pipeline developments is crucial before making any investment decisions.  The high expected return is encouraging for long-term investors but must be weighed against the inherent risks in the biotech sector.


**9. Disclaimer:** This report is for informational purposes only and should not be considered financial advice.  Investment decisions should be made based on your own research and risk tolerance.  Consult with a qualified financial advisor before making any investment decisions.
